ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...

In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

As part of an educational series on qualifying biomarkers for use in drug development, the US Food and Drug Administration (FDA) has released two fictitious examples of how biomarkers can improve the ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...

Panome Bio, a CRO, launched MassID™, a cloud-based computational platform designed to improve how researchers process and interpret untargeted LC/MS metabolomics data. The platform is described in a ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BrainScope, a leader in brain diagnostics, today announced the successful completion of the proof-of-concept phase for a novel brain activity-based biomarker for the ...